Federal Register: December 24, 2002 (Volume 67, Number 247)
DOCID: FR Doc 02-32347
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
NOTICE: NOTICES
ACTION: Patent licenses; non-exclusive, exclusive, or partially exclusive:
DOCUMENT ACTION: None.
SUBJECT CATEGORY:
Prospective Grant of Exclusive License: Methods and Compositions for the Promotion of Hair Growth Utilizing Actin Binding Peptides
DATES: Only written comments and/or license applications which are received by the National Institutes of Health on or before February 24, 2003, will be considered.
DOCUMENT SUMMARY:
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
[[Page 78489]]
404.7(a)(1)(i), that the National Institutes of Health, Department of
Health and Human Services, is contemplating the grant of an exclusive
license to practice the invention embodied in U.S. provisional patent
application 60/351,386 (DHHS ref. no. E0532002/0US01) filed January
25, 2002, and entitled ``Methods and compositions for the promotion of
hair growth utilizing actin binding peptides,'' to Lee's Pharmaceutical
(Hong Kong) Ltd. having a place of business in Hong Kong. The patent
rights in this invention have been assigned to the United States of America.
The prospective exclusive license territory will be China, Hong Kong and Taiwan. The field of use may be limited to use of actin binding peptides for the promotion of hair growth.
SUMMARY:
Lee's Pharmaceutical (Hong Kong) Ltd.,
SUPPLEMENTAL INFORMATION
The above-referenced patent application relates to the discovery of actin binding peptides that have been shown to promote hair growth. Specifically the patent application discloses a seven amino acid peptide of Thymosinbeta4 that promotes hair growth.
The prospective exclusive license will be royaltybearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within 60 days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: December 13, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 0232347 Filed 122302; 8:45 am]
BILLING CODE 414001P